Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer

Figure 1 Neutrophil-to-lymphocyte ratio fluctuation in patients who discontinued treatment after administering nivolumab < 6 times, who discontinued treatment after administering nivolumab 6-11 times, and who administered nivolumab ≥ 12 times. A: A significant increase in neutrophil-to-lymphocyte ratio (NLR) was observed at the discontinuation (n = 40, median NLR = 4.01 vs 5.92, P = 0.020); B: A significant increase in NLR was observed at the discontinuation (n = 32, median NLR = 3.03 vs 3.50, P = 0.038); C: No significant difference in NLR was observed between treatment initiation and the 12^th administration (n = 32, median NLR = 2.64 vs 2.32, P = 0.940). NLR: Neutrophil-to-lymphocyte ratio.